Vincenzo Vestuto

Dr. Vincenzo Vestuto

Department of Pharmacy, University of Salerno, Fisciano, Italy
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 March 2023 in Antioxidants
Verified
Journal Article
Open access
PDF file
PMPasquale Marino
Pasquale Marino
Giacomo PepeGiacomo Pepe
Giacomo Pepe
Manuela BasilicataManuela Basilicata
Manuela Basilicata
Vincenzo VestutoVincenzo Vestuto
Vincenzo Vestuto
STEFANIA MARZOCCOSTEFANIA MARZOCCO
STEFANIA MARZOCCO
Pietro CampigliaPietro Campiglia
Pietro Campiglia
Nutrition has a significant effect and a crucial role in disease prevention. Low consumption of fruit and vegetables and a sedentary lifestyle are closely related with the onset and development of many types of cancer. Recently, nutraceuticals have gained much attention in cancer research due to their pleiotropic effects and relatively non-toxic behavior. In fact, although in the past there have been conflicting results on the role of some antioxidant compounds as allies against cancer, numerous recent clinical studies highlight the efficacy of dietary phytochemicals in the prevention and treatment of cancer. However, further investigation is necessary to gain a deeper understanding of the potential anticancer capacities of dietary phytochemicals as well as the mechanisms of their action. Therefore, this review examined the current literature on the key properties of the bioactive components present in the diet, such as carotenoids, polyphenols, and antioxidant compounds, as well as their use in cancer therapy. The review focused on potential chemopreventive properties, evaluating their synergistic effects with anticancer drugs and, consequently, the side effects associated with current cancer treatments.

6 March 2022 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
DCDaniela Carbone
Daniela Carbone
Vincenzo VestutoVincenzo Vestuto
Vincenzo Vestuto
MFMaria Rosalia Ferraro
Maria Rosalia Ferraro
TCTania Ciaglia
Tania Ciaglia
CPCamilla Pecoraro
Camilla Pecoraro
COCarmine Ostacolo
Carmine Ostacolo

25 June 2025 in Biomolecules
Verified
Journal Article
Open access
PDF file
MVMariapia Vietri
Mariapia Vietri
MMMaria Rosaria Miranda
Maria Rosaria Miranda
Giuseppina AmodioGiuseppina Amodio
Giuseppina Amodio
TCTania Ciaglia
Tania Ciaglia
Alessia BertaminoAlessia Bertamino
Alessia Bertamino
OMOrnella Moltedo
Ornella Moltedo
Lysosomal dysfunction and endoplasmic reticulum (ER) stress play essential roles in cancer cell survival, growth, and stress adaptation. Among the various stressors in the tumor microenvironment, oxidative stress (OS) is a central driver that exacerbates both lysosomal and ER dysfunction. In healthy cells, the ER manages protein folding and redox balance, while lysosomes regulate autophagy and degradation. Cancer cells, however, are frequently exposed to elevated levels of reactive oxygen species (ROS), which disrupt protein folding in the ER and damage lysosomal membranes and enzymes, promoting dysfunction. Persistent OS activates the unfolded protein response (UPR) and contributes to lysosomal membrane permeabilization (LMP), leading to pro-survival autophagy or cell death depending on the context and on the modulation of pathways like PERK, IRE1, and ATF6. Cancer cells exploit these pathways by enhancing their tolerance to OS and shifting UPR signaling toward survival. Moreover, lysosomal impairment due to ROS accumulation compromises autophagy, resulting in the buildup of damaged organelles and further amplifying oxidative damage. This vicious cycle of ROS-induced ER stress and lysosomal dysfunction contributes to tumor progression, therapy resistance, and metabolic adaptation. Thus, targeting lysosomal and ER stress responses offers potential as cancer therapy, particularly in increasing oxidative stress and promoting apoptosis. This review explores the interconnected roles of lysosomal dysfunction, ER stress, and OS in cancer, focusing on the mechanisms driving their crosstalk and its implications for tumor progression and therapeutic resistance.

16 August 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
SMSimona Musella
Simona Musella
LCLidia Carotenuto
Lidia Carotenuto
Nunzio IraciNunzio Iraci
Nunzio Iraci
GBGiulia Baroli
Giulia Baroli
TCTania Ciaglia
Tania Ciaglia
FMFrancesco Miceli
Francesco Miceli
Neuronal Kv7 channels represent important pharmacological targets for hyperexcitability disorders including epilepsy. Retigabine is the prototype Kv7 activator clinically approved for seizure treatment; however, severe side effects associated with long-term use have led to its market discontinuation. Building upon the recently described cryoEM structure of Kv7.2 complexed with retigabine and on previous structure-activity relationship studies, a small library of retigabine analogues has been designed, synthesized, and characterized for their Kv7 opening ability using both fluorescence- and electrophysiology-based assays. Among all tested compounds, 60 emerged as a potent and photochemically stable neuronal Kv7 channel activator. Compared to retigabine, compound 60 displayed a higher brain/plasma distribution ratio, a longer elimination half-life, and more potent and effective anticonvulsant effects in an acute seizure model in mice. Collectively, these data highlight compound 60 as a promising lead compound for the development of novel Kv7 activators for the treatment of hyperexcitability diseases.

9 December 2019 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
COCarmine Ostacolo
Carmine Ostacolo
FMFrancesco Miceli
Francesco Miceli
VSVeronica Di Sarno
Veronica Di Sarno
PNPiera Nappi
Piera Nappi
Nunzio IraciNunzio Iraci
Nunzio Iraci
MTMaurizio Taglialatela
Maurizio Taglialatela

1 November 2022 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
ICIda Cerqua
Ida Cerqua
SMSimona Musella
Simona Musella
LPLukas Klaus Peltner
Lukas Klaus Peltner
Danilo D'AvinoDanilo D'Avino
Danilo D'Avino
VSVeronica Di Sarno
Veronica Di Sarno
Alessia BertaminoAlessia Bertamino
Alessia Bertamino
The design of multitarget drugs represents a promising strategy in medicinal chemistry and seems particularly suitable for the discovery of anti-inflammatory drugs. Here, we describe the identification of an indoline-based compound inhibiting both 5-lipoxygenase (5-LOX) and soluble epoxide hydrolase (sEH). In silico analysis of an in-house library identified nine compounds as potential 5-LOX inhibitors. Enzymatic and cellular assays revealed the indoline derivative 43 as a notable 5-LOX inhibitor, guiding the design of new analogues. These compounds underwent extensive in vitro investigation revealing dual 5-LOX/sEH inhibitors, with 73 showing the most promising activity (IC50s of 0.41 ± 0.01 and 0.43 ± 0.10 μM for 5-LOX and sEH, respectively). When challenged in vivo in zymosan-induced peritonitis and experimental asthma in mice, compound 73 showed remarkable anti-inflammatory efficacy. These results pave the way for the rational design of 5-LOX/sEH dual inhibitors and for further investigation of their potential use as anti-inflammatory agents.